On-line Table 1: Clinical and imaging data according to motor outcome at 3-month follow-up

On-line Table I: Clinical and imaging data according to motor outcome at 3-month follow-up  Good Motor Poor Motor					
		Outcome, mNIHSS	Outcome, mNIHSS	P	
Variables	Overall (n = 43)	(0-3) $(n=30)$	(4–8) (n = 13)	Value	
Female (No.) (%)	12 (27.9)	11 (36.7)	1(7.7)	.052	
Age (median) (IQR)	68 (57–76)	64.5 (55–73)	73 (67–76)	.252	
Hypertension (No.) (%)	31 (72.1)	23 (76.7)	8 (61.5)	.310	
Diabetes mellitus (No.) (%)	8 (18.6)	6 (20.0)	2 (15.4)	.721	
Leukocyte count (median) (IQR)	8.1 (5.88–10.86)	7.90 (5.55–10.64)	8.69 (8.00–10.90)	.161	
Fibrinogen (median) (IQR)	404 (315–459.5)	398 (301.75–444.75)	425 (347–479)	.294	
Body temperature (median) (IQR)	36 (36–36.5)	36 (36–36.5)	36.5 (35.8–36.55)	.799	
Platelet count (median) (IQR)	197 (151.5–261)	205 (180.5–267.75)	177 (141–243)	.281	
Antiplatelet treatment (No.) (%)	12 (27.9)	6 (23.3)	5 (38.5)	.310	
NIHSS score at admission (median) (IQR)	13 (8–17)	11 (5–15)	17 (14–19)	.005ª	
mNIHSS score at admission (median) (IQR)	5 (2–8)	4 (2–6)	8 (7–8)	.002ª	
NIHSS score at 72 hr (median) (IQR)	9 (2–16)	4.5 (1–10.75)	17 (13–18)	$<.001^{a}$	
mNIHSS score at 72 hr (median) (IQR)	3 (0–8)	1 (0–5)	8 (8–8)	<.001 <sup>a</sup>	
mRS at 3 mo (median) (IQR)	3 (1–4)	2 (1–3)	4 (4–4)	<.001 <sup>a</sup>	
NIHSS score at 3 mo (median) (IQR)	3 (1–7.5)	2 (0.25–3.75)	10 (8–12)	<.001 <sup>a</sup>	
Time from onset to MRI (median) (IQR) (min)	407 (238–559)	444 (313–623)	238 (167–399)	.005 <sup>a</sup>	
ICH right hemisphere (No.) (%)	3 (6.98)	3 (30.0)	0 (0)	.334	
ICH location (No.) (%)				.641	
Superficial	5 (11.9)	3 (10.3)	2 (15.38)		
Deep	37 (88.1)	26 (89.7)	11 (84.62)		
rFA at pons at admission	1 (0.89–1.17)	0.99 (0.89–1.19)	1.02 (0.91–1.14)	.966	
rRD at pons at admission	0.98 (0.83-1.13)	0.98 (0.81–1.12)	0.98 (0.83-1.16)	.862	
rMD at pons at admission	0.97 (0.93-1.06)	0.98 (0.94–1.06)	0.96 (0.83-1.06)	.610	
rAD at pons at admission	1.03 (0.92–1.1)	1.03 (0.92–1.1)	0.98 (0.92–1.11)	.686	
rFA at PLIC at admission	1.06 (0.95–1.2)	1.1 (0.95–1.21)	1 (0.94–1.09)	.200	
rRD at PLIC at admission	0.94 (0.82–1.1)	0.88 (0.78–1.07)	1.06 (0.87–1.35)	.085	
rMD at PLIC at admission	1.01 (0.94–1.13)	0.99 (0.92–1.11)	1.09 (1.03–1.16)	.072	
rAD at PLIC at admission	1.1 (1–1.16)	1.08 (0.95–1.13)	1.14 (1.07–1.24)	.060	
ICH volume at admission (median) (IQR) (mL)	12.66 (5.45–21.91)	10.45 (5.07–15.74)	22.74 (10.3–30)	.034ª	
PHE volume at admission (median) (IQR) (mL)	4.65 (1.83–11.19)	3.39 (1.48–11.12)	5.89 (3.46–14.88)	.418	
ICH volume at 24 hr (median) (IQR) (mL)	15.78 (7.06–29.32)	11.88 (6.5–17.85)	26.45 (10.3–35.84)	.087	
PHE volume at 24 hr (median) (IQR) (mL)	11.69 (6.1–22.4)	10.6 (6.1–18.91)	21.15 (9.47–48.35)	.133	
ICH growth (24 hr, baseline) (mL)	1 (0.08–2.82)	1.28 (0.19–1.98)	0.67 (0–4.54)	.869	
CST involvement by ICH at admission (No.) (%)	24 (55.8)	13 (43.33)	11 (84.61)	.016ª	
Centrum semiovale	4 (9.30)	0 (0)	4 (30.76)	.002ª	
Corona radiata	18 (41.86)	11 (36.66)	7 (53.84)	.335	
PLIC	14 (32.5)	5 (16.66)	9 (69.23)	.001 <sup>a</sup>	
CST involvement by PHE at admission (No.) (%)	33 (76.74)	25 (83.33)	8 (61.5)	.072	
Centrum semiovale	6 (13.95)	4 (13.33)	2 (15.38)	.892	
Corona radiata	29 (67.44)	22 (73.33)	7 (53.84)	.154	
PLIC	17 (39.53)	14 (46.66)	3 (23.07)	.124	

 $\textbf{Note:} \\ -\text{rMD indicates mean diffusivity ratio; rRD, radial diffusivity ratio; rAD, axial diffusivity ratio.}$ 

 $<sup>^{\</sup>rm a}\,{\rm Statistically}$  significant.

On-line Table 2: Clinical and imaging data according to functional outcome at 3-month follow-up

Variables	Good Outcome, mRS $0-2$ ( $n = 19$ )	Poor Outcome, mRS 3–5 (n = 24)	P Value
Female (No.) (%)	8 (42.1)	4 (16.7)	.065
Age (median) (IQR)	62 (50–70.5)	72 (61.25–76)	.089
Hypertension (No.) (%)	14 (73.7)	17 (70.8)	.836
Diabetes mellitus (No.) (%)	4 (21.1)	4 (16.7)	.714
Leukocyte count (median) (IQR)	8.1 (5.73–9.95)	8.35 (6.10–11.18)	.509
Fibrinogen (median) (IQR)	384 (299.5–429.5)	430 (343.25–471.5)	.14
Body temperature (median) (IQR)	36.2 (36–36.7)	36 (36–36.5)	.332
Platelet count (median) (IQR)	197 (183.5–261.5)	200 (146.8–255)	.642
Antiplatelet use (No.) (%)	4 (21.1)	8 (33.3)	.373
NIHSS score at admission (median) (IQR)	10 (4–15.5)	15 (10.5–18)	.016ª
mNIHSS score at admission (median) (IQR)	3 (2–6.5)	6.5 (4–8)	.019ª
NIHSS score at 72 hr (median) (IQR)	2 (1–5)	14 (9–17.25)	$< .001^{a}$
mNIHSS score at 72 hr (median) (IQR)	0 (0–1)	7.5 (5–8)	$<.001^{a}$
mRS at 3 mo (median) (IQR)	1 (1–2)	4 (3–4)	$<.001^{a}$
NIHSS score at 3 mo (median) (IQR)	1 (0-2)	7 (5–11)	$<.001^{a}$
Time from onset to MRI (median) (IQR) (min)	444 (312.5–584.5)	367 (228–525.5)	.197
ICH right hemisphere (No.) (%)	2 (40.0)	1 (14.3)	.310
ICH location (No.) (%)			.227
Superficial	1 (5.3)	4 (17.4)	
Deep	18 (94.7)	19 (82.6)	
rFA at pons at admission	0.98 (0.9–1.16)	1.04 (0.89–1.17)	.957
rRD at pons at admission	0.99 (0.82–1.1)	0.97 (0.83–1.14)	.753
rMD at pons at admission	0.97 (0.94–1.07)	0.99 (0.88–1.06)	.586
rAD at pons at admission	1.07 (0.91–1.15)	1 (0.92–1.09)	.460
rFA at PLIC at admission	1.13 (0.98–1.3)	1 (0.93–1.14)	.143
rRD at PLIC at admission	0.82 (0.75–1.05)	0.94 (0.85–1.14)	.070
rMD at PLIC at admission	0.97 (0.93–1.09)	1.05 (0.98–1.15)	.054
rAD at PLIC at admission	1.06 (0.99–1.11)	1.13 (1.04–1.21)	.156
ICH volume at admission (median) (IQR) (mL)	6.69 (4.53–13.11)	18 (10.03–29.82)	.004ª
PHE volume at admission (median) (IQR) (mL)	3.07 (2.2–6.79)	6.3 (1.7–21.66)	.27
ICH volume at 24 hr (median) (IQR) (mL)	11.53 (6.24–15.9)	20.2 (10.59–35.65)	.036ª
PHE volume at 24 hr (median) (IQR) (mL)	10.6 (4.55–13.12)	21.05 (7.07–35.09)	.121
ICH growth (24 hr, baseline) (mL)	0.7 (0.18–2.09)	1.3 (0.02–3.02)	.91
CST involvement by ICH at admission (No.) (%)	8 (42.1)	16 (69.6)	.073
Centrum semiovale	0 (0)	4 (17.4)	.056
Corona radiata	8 (42.1)	10 (43.5)	.929
PLIC	2 (10.5)	12 (52.1)	.004ª
CST involvement by PHE at admission (No.) (%)	17 (89.5)	16 (69.6)	.118
Centrum semiovale	3 (15.8)	3 (13.0)	.800
Corona radiata	15 (78.9)	14 (60.9)	.207
PLIC	9 (47.4)	8 (34.8)	.408

**Note:**—rMD indicates mean diffusivity ratio; rRD, radial diffusivity ratio; rAD, axial diffusivity ratio.

 $<sup>^{\</sup>rm a}\,{\rm Statistically}$  significant.